Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ROSE-010 · 1 trial · 1 indication
The amount of food (weight and energy content) consumed during lunch after administration of ROSE-010 at 2 dose levels compared to placebo.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Saline solution |
| ROSE-010 99 mcg | EXPERIMENTAL | ROSE-010 solution, 99 mcg, 0.5 ml |
| ROSE-010 150 mcg | EXPERIMENTAL | ROSE-010 solution, 150 mcg, 0.5 ml |
| Name | Type | Description |
|---|---|---|
| ROSE-010 99 mcg | DRUG | Sub-cutaneous injection of ROSE-010 solution |
| Placebo | DRUG | Sub-cutaneous injection of saline solution |
| ROSE-010 150 mcg | DRUG | Sub-cutaneous injection of ROSE-010 solution |
Inclusion Criteria: 1. Body mass index greater or equal to 27 and less than nor equal to 35 kg/m2 at Screening. 2. Good health, as assessed by the Investigator, based on medical, surgical, and psychiatric history, physical examination, 12-lead electrocardiogram (ECG), vital sign assessments, and cl...
ROSE-010 is an investigational small molecule being developed for the treatment of obesity and overweight. It is currently in Phase 2 clinical development, with a completed trial studying its effect on appetite in overweight and obese subjects.
ROSE-010 is a GLP-1 analogue, meaning it targets the glucagon-like peptide-1 receptor. By acting on this target, it is being studied for its potential to affect appetite in individuals who are overweight or obese.
ROSE-010 is being developed by Soligenix, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SNGX. The company is conducting clinical research to evaluate the drug's effects on appetite in overweight and obese populations.
ROSE-010 is in Phase 2 clinical development. A Phase 2 trial has been completed, which was a randomized, double-blind, placebo-controlled study involving 40 female participants in the United States. The drug is not yet approved and remains investigational.
ROSE-010 has one completed Phase 2 clinical trial, identified as NCT06621017, titled 'Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects.' The study enrolled 40 participants, was randomized, double-blind, and placebo-controlled, and took place in the United States.
Yes, ROSE-010 is described as a GLP-1 analogue. It is being studied for its effects on appetite in overweight and obese individuals, and the completed Phase 2 trial (NCT06621017) specifically evaluated its impact on appetite in this population.